| Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells S Arora, A Kothandapani, K Tillison, V Kalman-Maltese, SM Patrick DNA repair 9 (7), 745-753, 2010 | 229 | 2010 |
| Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors S Arora, R Velichinskii, RW Lesh, U Ali, M Kubiak, P Bansal, H Borghaei, ... Advances in therapy 36, 2638-2678, 2019 | 189 | 2019 |
| Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients IG Serebriiskii, C Connelly, G Frampton, J Newberg, M Cooke, V Miller, ... Nature communications 10 (1), 3722, 2019 | 175 | 2019 |
| POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies E Nicolas, EA Golemis, S Arora Gene 590 (1), 128-141, 2016 | 123 | 2016 |
| Reversible cell cycle inhibition and premature aging features imposed by conditional expression of p16Ink4a sanjeevani arora Aging Cell, 2015 | 71 | 2015 |
| Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells S Arora, J Heyza, H Zhang, V Kalman-Maltese, K Tillison, AM Floyd, ... Oncotarget 7 (46), 75104, 2016 | 58 | 2016 |
| Gap junction intercellular communication positively regulates cisplatin toxicity by inducing DNA damage through bystander signaling S Arora, JR Heyza, EC Chalfin, RJ Ruch, SM Patrick Cancers 10 (10), 368, 2018 | 39 | 2018 |
| Genetic variants that predispose to DNA double-strand breaks in lymphocytes from a subset of patients with familial colorectal carcinomas S Arora, H Yan, I Cho, HY Fan, B Luo, X Gai, DL Bodian, JG Vockley, ... Gastroenterology 149 (7), 1872-1883. e9, 2015 | 39 | 2015 |
| Targeting the DNA repair endonuclease ERCC1-XPF with green tea polyphenol epigallocatechin-3-gallate (EGCG) and its prodrug to enhance cisplatin efficacy in human cancer cells JR Heyza, S Arora, H Zhang, KL Conner, W Lei, AM Floyd, RR Deshmukh, ... Nutrients 10 (11), 1644, 2018 | 38 | 2018 |
| Functional analysis of rare variants in mismatch repair proteins augments results from computation-based predictive methods S Arora, PJ Huwe, R Sikder, M Shah, AJ Browne, R Lesh, E Nicolas, ... Cancer Biology & Therapy 18 (7), 519-533, 2017 | 24 | 2017 |
| Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer TR Hartman, EV Demidova, RW Lesh, L Hoang, M Richardson, A Forman, ... Scientific Reports 10 (1), 13518, 2020 | 16 | 2020 |
| Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer E Nicolas, S Arora, Y Zhou, IG Serebriiskii, MD Andrake, ED Handorf, ... Oncotarget 6 (37), 39614, 2015 | 14 | 2015 |
| Interaction of germline variants in a family with a history of early‐onset clear cell renal cell carcinoma E Nicolas, EV Demidova, W Iqbal, IG Serebriiskii, R Vlasenkova, ... Molecular Genetics & Genomic Medicine 7 (3), e556, 2019 | 13 | 2019 |
| RRM2B is frequently amplified across multiple tumor types: implications for DNA repair, cellular survival, and cancer therapy W Iqbal, EV Demidova, S Serrao, T ValizadehAslani, G Rosen, S Arora Frontiers in genetics 12, 628758, 2021 | 10 | 2021 |
| Polλ promotes microhomology-mediated end-joining G Chandramouly, J Jamsen, N Borisonnik, M Tyagi, ML Calbert, ... Nature structural & molecular biology 30 (1), 107-114, 2023 | 9 | 2023 |
| Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology SM Shah, EV Demidova, RW Lesh, MJ Hall, MB Daly, JE Meyer, ... Cancer treatment reviews 104, 102337, 2022 | 8 | 2022 |
| A new strategy to ERADicate HER2-positive breast tumors? S Arora, EA Golemis Science signaling 8 (378), fs11-fs11, 2015 | 7 | 2015 |
| The landscape of POLE variants in colorectal and endometrial tumors: Correlation with microsatellite instability (MSI) and tumor mutation burden (TMB). S Arora, J Xiu, D Sohal, E Lou, RM Goldberg, BA Weinberg, A Grothey, ... Journal of clinical oncology 38 (15_suppl), e13538-e13538, 2020 | 5 | 2020 |
| Patterns of germline and somatic testing after universal tumor screening for Lynch syndrome: A clinical practice survey of active members of the Collaborative Group of the … R Hodan, L Rodgers‐Fouche, S Arora, M Dominguez‐Valentin, P Kanth, ... Journal of genetic counseling 31 (4), 949-955, 2022 | 3 | 2022 |
| Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP? EV Demidova, P Ghatalia, S Arora European urology 81 (2), 149-150, 2022 | 3 | 2022 |
Erica GolemisProfessor, Assoc. Director for System Integration, Fox Chase Cancer Center, and Chair, LKSOM在 fccc.edu 的电子邮件经过验证
